Cargando…

The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study

GCSF prophylaxis is recommended in patients on chemotherapy with a >20% risk of febrile neutropenia and is to be considered if there is an intermediate risk of 10–20%. GCSF has been suggested as a possible adjunct to immunotherapy due to increased peripheral neutrophil recruitment and PD-L1 expre...

Descripción completa

Detalles Bibliográficos
Autores principales: Anpalakhan, Shobana, Huddar, Prerana, Behrouzi, Roya, Signori, Alessio, Cave, Judith, Comins, Charles, Cortellini, Alessio, Addeo, Alfredo, Escriu, Carles, McKenzie, Hayley, Barone, Gloria, Murray, Lisa, Bhatnagar, Gagan, Pinato, David J., Ottensmeier, Christian, Gomes, Fabio, Banna, Giuseppe Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867035/
https://www.ncbi.nlm.nih.gov/pubmed/36675262
http://dx.doi.org/10.3390/ijms24021746
_version_ 1784876242166611968
author Anpalakhan, Shobana
Huddar, Prerana
Behrouzi, Roya
Signori, Alessio
Cave, Judith
Comins, Charles
Cortellini, Alessio
Addeo, Alfredo
Escriu, Carles
McKenzie, Hayley
Barone, Gloria
Murray, Lisa
Bhatnagar, Gagan
Pinato, David J.
Ottensmeier, Christian
Gomes, Fabio
Banna, Giuseppe Luigi
author_facet Anpalakhan, Shobana
Huddar, Prerana
Behrouzi, Roya
Signori, Alessio
Cave, Judith
Comins, Charles
Cortellini, Alessio
Addeo, Alfredo
Escriu, Carles
McKenzie, Hayley
Barone, Gloria
Murray, Lisa
Bhatnagar, Gagan
Pinato, David J.
Ottensmeier, Christian
Gomes, Fabio
Banna, Giuseppe Luigi
author_sort Anpalakhan, Shobana
collection PubMed
description GCSF prophylaxis is recommended in patients on chemotherapy with a >20% risk of febrile neutropenia and is to be considered if there is an intermediate risk of 10–20%. GCSF has been suggested as a possible adjunct to immunotherapy due to increased peripheral neutrophil recruitment and PD-L1 expression on neutrophils with GCSF use and greater tumour volume decrease with higher tumour GCSF expression. However, its potential to increase neutrophil counts and, thus, NLR values, could subsequently confer poorer prognoses on patients with advanced NSCLC. This analysis follows on from the retrospective multicentre observational cohort Spinnaker study on advanced NSCLC patients. The primary endpoints were OS and PFS. The secondary endpoints were the frequency and severity of AEs and irAEs. Patient information, including GCSF use and NLR values, was collected. A secondary comparison with matched follow-up duration was also undertaken. Three hundred and eight patients were included. Median OS was 13.4 months in patients given GCSF and 12.6 months in those not (p = 0.948). Median PFS was 7.3 months in patients given GCSF and 8.4 months in those not (p = 0.369). A total of 56% of patients receiving GCSF had Grade 1–2 AEs compared to 35% who did not receive GCSF (p = 0.004). Following an assessment with matched follow-up, 41% of patients given GCSF experienced Grade 1–2 irAEs compared to 23% of those not given GCSF (p = 0.023). GCSF prophylaxis use did not significantly affect overall or progression-free survival. Patients given GCSF prophylaxis were more likely to experience Grade 1–2 adverse effects and Grade 1–2 immunotherapy-related adverse effects.
format Online
Article
Text
id pubmed-9867035
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98670352023-01-22 The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study Anpalakhan, Shobana Huddar, Prerana Behrouzi, Roya Signori, Alessio Cave, Judith Comins, Charles Cortellini, Alessio Addeo, Alfredo Escriu, Carles McKenzie, Hayley Barone, Gloria Murray, Lisa Bhatnagar, Gagan Pinato, David J. Ottensmeier, Christian Gomes, Fabio Banna, Giuseppe Luigi Int J Mol Sci Article GCSF prophylaxis is recommended in patients on chemotherapy with a >20% risk of febrile neutropenia and is to be considered if there is an intermediate risk of 10–20%. GCSF has been suggested as a possible adjunct to immunotherapy due to increased peripheral neutrophil recruitment and PD-L1 expression on neutrophils with GCSF use and greater tumour volume decrease with higher tumour GCSF expression. However, its potential to increase neutrophil counts and, thus, NLR values, could subsequently confer poorer prognoses on patients with advanced NSCLC. This analysis follows on from the retrospective multicentre observational cohort Spinnaker study on advanced NSCLC patients. The primary endpoints were OS and PFS. The secondary endpoints were the frequency and severity of AEs and irAEs. Patient information, including GCSF use and NLR values, was collected. A secondary comparison with matched follow-up duration was also undertaken. Three hundred and eight patients were included. Median OS was 13.4 months in patients given GCSF and 12.6 months in those not (p = 0.948). Median PFS was 7.3 months in patients given GCSF and 8.4 months in those not (p = 0.369). A total of 56% of patients receiving GCSF had Grade 1–2 AEs compared to 35% who did not receive GCSF (p = 0.004). Following an assessment with matched follow-up, 41% of patients given GCSF experienced Grade 1–2 irAEs compared to 23% of those not given GCSF (p = 0.023). GCSF prophylaxis use did not significantly affect overall or progression-free survival. Patients given GCSF prophylaxis were more likely to experience Grade 1–2 adverse effects and Grade 1–2 immunotherapy-related adverse effects. MDPI 2023-01-16 /pmc/articles/PMC9867035/ /pubmed/36675262 http://dx.doi.org/10.3390/ijms24021746 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Anpalakhan, Shobana
Huddar, Prerana
Behrouzi, Roya
Signori, Alessio
Cave, Judith
Comins, Charles
Cortellini, Alessio
Addeo, Alfredo
Escriu, Carles
McKenzie, Hayley
Barone, Gloria
Murray, Lisa
Bhatnagar, Gagan
Pinato, David J.
Ottensmeier, Christian
Gomes, Fabio
Banna, Giuseppe Luigi
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study
title The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study
title_full The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study
title_fullStr The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study
title_full_unstemmed The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study
title_short The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study
title_sort effects of gcsf primary prophylaxis on survival outcomes and toxicity in patients with advanced non-small cell lung cancer on first-line chemoimmunotherapy: a sub-analysis of the spinnaker study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867035/
https://www.ncbi.nlm.nih.gov/pubmed/36675262
http://dx.doi.org/10.3390/ijms24021746
work_keys_str_mv AT anpalakhanshobana theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT huddarprerana theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT behrouziroya theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT signorialessio theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT cavejudith theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT cominscharles theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT cortellinialessio theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT addeoalfredo theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT escriucarles theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT mckenziehayley theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT baronegloria theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT murraylisa theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT bhatnagargagan theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT pinatodavidj theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT ottensmeierchristian theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT gomesfabio theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT bannagiuseppeluigi theeffectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT anpalakhanshobana effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT huddarprerana effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT behrouziroya effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT signorialessio effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT cavejudith effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT cominscharles effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT cortellinialessio effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT addeoalfredo effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT escriucarles effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT mckenziehayley effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT baronegloria effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT murraylisa effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT bhatnagargagan effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT pinatodavidj effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT ottensmeierchristian effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT gomesfabio effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy
AT bannagiuseppeluigi effectsofgcsfprimaryprophylaxisonsurvivaloutcomesandtoxicityinpatientswithadvancednonsmallcelllungcanceronfirstlinechemoimmunotherapyasubanalysisofthespinnakerstudy